The Week in Review: September 18-22
From violence risk assessment in emergency departments to connections between bipolar disorder and substance use disorders, here are highlights from the week in Psychiatric Times.
Psychedelics Research Roundup: September 22
What is new in research on psychedelics?
Phase 3 Study Supports Efficacy, Safety of New Chemical Entity for MDD
The investigators noted fast, clinically meaningful, and sustained improvements in symptoms of depression and related functional impairment.
Antipsychotic Medication for Parkinson Disease Psychosis Receives Packaging Label Updates
The drug’s developer announced that the FDA has made 2 clarifying revisions.
How Do Treatments for Bipolar Disorder and SUD Affect One Another?
An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.
The Week in Review: September 11-15
From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.
Special Populations Research Roundup: September 15
What is new in research on psychiatric care for Latinx patient populations?
Exploring the Neural Mechanisms Underlying PTSD in World Trade Center Responders
“Our findings might inform PTSD pathology, treatment plans, and future disaster-response strategies.”
Study Supports Long-Term Efficacy of Esketamine Nasal Spray in Patients With TRD
Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.
Study Compares Work Productivity Loss, Cost Savings in Esketamine Nasal Spray vs Quetiapine Extended-Release for TRD
“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”
The Week in Review: September 4-8
From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.
ADHD Research Roundup: September 8
What is new in research on attention-deficit/hyperactivity disorder?
Study Explores Effects of Sleep Robot Intervention on Patients With ADHD and Insomnia
The study explored the intervention’s effects using both quantitative and qualitative methods.
Next Steps for Zuranolone as a Treatment for MDD
The drug’s developers respond to the FDA’s decision to deny approval and consider future directions for this indication.
The Week in Review: August 28-September 1
From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.
TMS Research Roundup: September 1
What is new in research on transcranial magnetic stimulation?
From the Pages of Psychiatric Times: August 2023
The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.
Study Supports Psilocybin as Promising Treatment for MDD
The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.
NIDA Awards Grant of Up to $16.6M for Research on Investigational OUD Treatment
The funds will be distributed over the course of 5 years to support preclinical through phase 2 studies.
FDA Approves First Generics for the Treatment of ADHD, BED
Generics are now approved for adults in the treatment of BED and for individuals aged 6 years and older in the treatment of ADHD.
The Week in Review: August 21-25
From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.
MDD Research Roundup: August 25
What is new in research on major depressive disorder?
Research on Evenamide as a Treatment for TRS Reviewed in Highlights From First Half of 2023
Report reviews key study results and provides updates on additional studies in development.
Study Shows That Anti-Fentanyl Antibody Reverses Signs of Carfentanil Overdose
“We expect this antibody to be a valuable new weapon for fighting the opioid crisis.”
Exploring the Genetics of Schizophrenia
Awais Aftab, MD, interviews Audrey Clare Farley, PhD, author of Girls and Their Monsters: The Genain Quadruplets and the Making of Madness in America.
Study Explores Efficacy of rTMS on Response and Remission Rates in Patients With TRD
Investigators also concluded that rTMS may be effective as an adjunctive treatment for patients with MDD.
FDA Approves First Oral Treatment for Postpartum Depression in Adults
The FDA did not grant approval for the treatment for major depressive disorder.
Schizophrenia Treatment Fails to Meet Primary Endpoint in Phase 3 Clinical Studies
Although ulotaront was well-tolerated, results for patients treated with it were not superior to those for patients treated with placebo.
Addressing Racial and Ethnic Disparities in Women’s Mental Health Care
"Systemic racism is insidious and ingrained in our daily experience. Women of color are doubly minoritized."
Study Supports Neuroprotective, Disease-Modifying Effects of Clinical Drug Candidate in the Treatment of Alzheimer Disease
“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”
2 Clarke Drive Cranbury, NJ 08512